pharmaceuticals
pharmaceuticals Articles
Kura Oncology has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Published:
Corbus Pharmaceuticals announced that the FDA has designated as a Fast Track development program and granted Orphan Drug Designation to the its investigational new drug Resunab.
Published:
Cowen says the way to play biotech is with large cap sector leaders that can beat earnings estimates. It also thinks third-quarter earnings beats could highlight the risk of not owning biotech now.
Published:
MyoKardia expects to price more than 4 million shares in the range of $15 to $17 in an IPO valued up to more than $91 million.
Published:
Valeant Pharmaceuticals reported its third-quarter financial results before the markets opened on Monday.
Published:
Over the past week, a few biotech companies, such as Cepheid and Valeant Pharmaceuticals, made absolutely massive runs.
Published:
Cempra made waves in the market on Friday morning on Phase 3 trial news. Despite announcing positive top-line results, shares plunged by a third.
Published:
Appellis Pharmaceuticals has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering.
Published:
Axsome Therapeutics has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Published:
Can-Fite BioPharma announced that it has entered into definitive agreements with existing institutional investors in regard to a secondary offering.
Published:
Nabriva Therapeutics entered the market in mid-September, and now the quiet period has passed, allowing the underwriters can make calls.
Published:
Dimension Therapeutics expects to offer 5.5 million shares within the price range of $14 to $16 in an IPO valued up to $101.2 million.
Published:
Johnson & Johnson is scheduled to report its third-quarter financial results before the markets open on Tuesday.
Published:
Can-Fite Biopharma announced that its oncology drug candidate has been granted Orphan Drug Designation by the European Medicines Agency (EMA).
Published:
Wave Life Sciences has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Published: